PTC Therapeutics at Morgan Stanley conference: sephience drives outlook

At the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026, PTC Therapeutics (PTC) presented an updated outlook, highlighting the company's shift towards a diversified rare disease focus with its new product, Sephience. The presentation emphasized positive growth prospects, despite challenges in PTC's historical Duchenne muscular dystrophy (DMD) division.

Management communicated optimism by raising the 2026 revenue guidance to $850 million to $950 million, signaling confidence in the company's financial trajectory. Additionally, they disclosed that the company expects to reach cash flow breakeven this year. PTC's cash reserves stand at $2.2 billion after acquiring ST-920 for $111 million upfront.

The spotlight of the presentation was on Sephience, a therapy for phenylketonuria (PKU), which has exceeded expectations since its launch just over a year ago. The therapy has already outperformed earlier PKU products, such as KUVAN and PALYNZIQ. More than 2,000 patients have enrolled, with 30% coming from the treatment-naive population. PTC reported 100% penetration across the original 100 U.S. centers of excellence, with 80% of patients attending these centers.

Management argued that Sephience is reaching patients across the entire PKU spectrum, including those with severe disease and those who have never received treatment before. They highlighted that the drug has become increasingly popular as first-line therapy, with a discontinuation rate of about 20%, in line with clinical trial expectations of around 25%.

Sephience's global reach includes an estimated 17,000 PKU patients in the U.S. and a global PKU population of approximately 58,000. The drug has been approved in the U.S., Europe, and Japan within six months, with Germany currently in pricing and reimbursement discussions. Investors were encouraged by PTC's strong financial flexibility, a robust liquidity position, and the company's ability to manage expenses in line with revenue growth.